With me here in Charlotte are RXO's Chief Financial Officer, James E. Harris, and Chief Strategy Officer, Jared Ian Weisfeld.

Recent updates around Bristol Myers Squibb have nudged the fair value estimate to US$58.13 from US$56.26, a modest shift that reflects refreshed assumptions on risk, revenue trends, and how much of ...